leadf
logo-loader
viewXPhyto Therapeutics Corp.

XPhyto Therapeutics looking forward to "transformational" 2021 as it stands on the cusp of commercialization

The life sciences accelerator is moving its product development programs, including a rapid COVID-19 PCR test and drug formulation products, through the laboratory and into the clinic

XPhyto Therapeutics Corp. -
XPhyto is hoping to launch the rapid PCR test in the first quarter of 2021

XPhyto Therapeutics Corp (CSE:XPHY) (OTCQB:XPHYF) (FRA:4XT) is moving closer to commercializing its rapid COVID-19 PCR test in 2021, it told shareholders Monday. 

In a business update, the life sciences accelerator said that it is “on the cusp of transformational change” as its product development programs, including the rapid PCR test, move through the laboratory and into the clinic.

Vancouver-based XPhyto and its German development partner 3a-diagnostics GmbH, are hoping to launch the rapid PCR test in the first quarter of 2021.  The two companies are also developing and commercializing several low-cost oral biosensors targeted for commercial approval and product launch in late 2021. 

READ: XPhyto Therapeutics and German partner complete successful validation of their COVID-19 RT-PCR test system

Things look busy on the drug formulations front as well, with plans to launch human pilot studies on four of XPhyto’s lead therapeutic products: a transdermal patch for Parkinson’s disease; a CBD oral/sublingual strip for treatment-resistant epilepsy; a THC oral/sublingual strip for anorexia and nausea, and a CBD:THC (1:1) oral/sublingual strip for multiple sclerosis-related spasticity.

As for XPhyto’s psychedelics initiatives, the company said it plans to expand its programs to produce psychedelic APIs on an industrial scale. In addition, it plans to launch new programs to develop psychedelic drug formulations, as well as integrate the therapeutic products into established clinical care programs for mental health-related indications.

XPhyto CEO Hugh Rogers told investors that the firm had made significant progress in its business initiatives in 2020.

"We have ambitious milestones for 2021 with multiple product launches on the horizon, multiple clinical drug programs underway, and an aggressive commitment to psychedelic medicine,” Rogers said in a statement. “I am extremely confident that our team can execute on the company's business plan for 2021."

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: XPhyto Therapeutics Corp.

Price: 2.86 CAD

CSE:XPHY
Market: CSE
Market Cap: $183.08 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

XPhyto Therapeutics achieves first purchases for their 25 minute PCR test

XPhyto Therapeutics (CSE: XPHY- OTCQB: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive with news the company has received the first purchases of their 25 minute rapid PCR test which is being manufactured in Germany. These tests will be used for regulatory approvals in a number...

6 days, 22 hours ago

2 min read